WO2011126882A9 - Therapeutic peptides and their derivatives and therapeutic uses thereof - Google Patents

Therapeutic peptides and their derivatives and therapeutic uses thereof Download PDF

Info

Publication number
WO2011126882A9
WO2011126882A9 PCT/US2011/030511 US2011030511W WO2011126882A9 WO 2011126882 A9 WO2011126882 A9 WO 2011126882A9 US 2011030511 W US2011030511 W US 2011030511W WO 2011126882 A9 WO2011126882 A9 WO 2011126882A9
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic
derivatives
peptides
therapeutic uses
therapeutic peptides
Prior art date
Application number
PCT/US2011/030511
Other languages
French (fr)
Other versions
WO2011126882A2 (en
Inventor
Cohava Gelber
John R. Simms
Gary Musso
Soren Mogelsvang
Original Assignee
American Type Culture Collection
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Type Culture Collection filed Critical American Type Culture Collection
Publication of WO2011126882A2 publication Critical patent/WO2011126882A2/en
Publication of WO2011126882A9 publication Critical patent/WO2011126882A9/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
PCT/US2011/030511 2010-03-30 2011-03-30 Therapeutic peptides and their derivatives and therapeutic uses thereof WO2011126882A2 (en)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US31917210P 2010-03-30 2010-03-30
US31897910P 2010-03-30 2010-03-30
US31912810P 2010-03-30 2010-03-30
US31891710P 2010-03-30 2010-03-30
US31906410P 2010-03-30 2010-03-30
US31897110P 2010-03-30 2010-03-30
US61/319,128 2010-03-30
US61/319,064 2010-03-30
US61/318,979 2010-03-30
US61/318,971 2010-03-30
US61/319,172 2010-03-30
US61/318,917 2010-03-30
US42245210P 2010-12-13 2010-12-13
US61/422,452 2010-12-13

Publications (2)

Publication Number Publication Date
WO2011126882A2 WO2011126882A2 (en) 2011-10-13
WO2011126882A9 true WO2011126882A9 (en) 2012-04-12

Family

ID=44763500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/030511 WO2011126882A2 (en) 2010-03-30 2011-03-30 Therapeutic peptides and their derivatives and therapeutic uses thereof

Country Status (1)

Country Link
WO (1) WO2011126882A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6416627B2 (en) * 2012-01-09 2018-10-31 セルピン ファーマ リミテッド ライアビリティ カンパニー Peptides and uses thereof
AU2013234955A1 (en) 2012-03-23 2014-11-13 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
WO2014197524A2 (en) * 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
EP3019188B1 (en) * 2013-07-08 2022-03-09 The University of Utah Research Foundation A peptide and the use thereof in the treatment of inflammatory disorders
GB201314610D0 (en) * 2013-08-15 2013-10-02 Blueberry Therapeutics Ltd Compounds and their uses
WO2017040287A1 (en) 2015-08-28 2017-03-09 Serpin Pharma, Llc Methods for treatment of diseases
CN112351989B (en) * 2018-07-11 2024-03-26 免疫制药有限公司 Peptide compounds and therapeutic uses thereof
EP4003391A4 (en) * 2020-07-06 2023-02-22 Serpin Pharma, LLC Peptides and methods of using the same

Also Published As

Publication number Publication date
WO2011126882A2 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
HK1223835A1 (en) Concentrated protein formulations and uses thereof
EP2542086A4 (en) Compounds and therapeutic uses thereof
IL222027A (en) Peptides and their use
IL223667B (en) S100a4 antibodies and therapeutic uses thereof
EP2601996A4 (en) Therapeutic instrument and attachment thereof
EP2605786A4 (en) Therapeutic peptides
EP2593595A4 (en) Novel peptides and uses thereof
WO2011126882A9 (en) Therapeutic peptides and their derivatives and therapeutic uses thereof
EP2892913A4 (en) Peptides and their uses
PL2627668T3 (en) Peptides and uses
AU2011259204A8 (en) Antigen peptide and use thereof
AU2011259204A1 (en) Antigen peptide and use thereof
EP2660249A4 (en) Peptide derivative and use thereof
EP2597084A4 (en) N-hydroxyformamide derivative and pharmaceutical containing same
WO2011087491A9 (en) Parstatin peptides and uses thereof
IL220859A0 (en) Alkyl-heterocycle-carbamate derivatives, their preparation and therapeutic application
AU2010904801A0 (en) Seleno-Compounds and Therapeutic Uses Thereof
AU2010901846A0 (en) Therapeutic methods and compositions
EP2638160B8 (en) Nuclions and ribocapsids
ZA201301674B (en) Novel methylcyclohexane derivatives and uses thereof
AU2011904672A0 (en) Therapeutic Compounds and Uses Thereof
AU2010902849A0 (en) Compounds and Therapeutic Applications Therefor
AU2010900699A0 (en) Therapeutic Uses of SLIRP
AU2010901509A0 (en) Shocktec gel and air2gel
AU2010903564A0 (en) Therapeutic pillow

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11766494

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11766494

Country of ref document: EP

Kind code of ref document: A2